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Abstract 22 
While placental function is fundamental to normal fetal development, the blood-brain barrier 23 
provides a second checkpoint critical to protecting the fetal brain and ensuring healthy brain 24 
development. The placenta is considered the key barrier between the mother and fetus, 25 
regulating delivery of essential nutrients, removing waste as well as protecting the fetus from 26 
potentially noxious substances. However, disturbances to the maternal environment and 27 
subsequent adaptations to placental function may render the placenta ineffective for 28 
providing a suitable environment for the developing fetus and to providing sufficient 29 
protection from harmful substances. The developing brain is particularly vulnerable to 30 
changes in the maternal/fetal environment. Development of the blood-brain barrier and 31 
maturation of barrier transporter systems work to protect the fetal brain from exposure to 32 
drugs, excluding them from the fetal CNS. This review will focus on the role of the ‘other’ 33 
key barrier during gestation – the blood-brain barrier – which has been shown to be 34 
functional as early as 8 weeks’ gestation.  35 
    36 
 37 
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 47 
Introduction 48 
There are a number of physiological barriers present in the body throughout life. Arguably 49 
the most important during pregnancy and the development of the fetus is the blood-placental 50 
barrier. The placenta forms the primary barrier between the maternal environment and the 51 
fetus regulating a wide variety of functions required for healthy development including gas 52 
exchange, hormone production and secretion and transfer of nutrients and waste [1, 2]. The 53 
placenta is essential for survival; it is responsible for stimulating the maternal endocrine 54 
system to release hormones necessary for the continuation of pregnancy but also functions to 55 
provide protection of the fetus from potentially harmful agents. The placenta plays a key role 56 
in adaption during pregnancy, responding and adjusting throughout to signals from both the 57 
mother and the fetus to ensure optimal growth and is essential to the development of the fetal 58 
brain [3]. Both intrinsic and extrinsic factors from the maternal environment result in 59 
modulation of intra-uterine development. In addition to the placenta however, other barrier 60 
systems exist in the fetus. The blood-brain barrier (BBB) is vital for protection of the brain 61 
and fundamental for the effective function of the central nervous system (CNS). 62 
 63 
The BBB is the interface between the systemic circulation and brain parenchyma. It is 64 
responsible for the regulation of movement between the two compartments and is essential 65 
for maintaining homeostasis in the CNS. The brain requires a carefully maintained 66 
microenvironment and protection from toxic endogenous and exogenous substances for 67 
normal function. While the placenta provides the first regulatory barrier between the mother 68 
and fetus, the BBB serves as a highly specific safeguard of the developing fetal brain. The 69 
placenta and BBB work to protect the fetus from potentially toxic substances which can have 70 
long term pathological consequences. To date, our understanding of the development and 71 
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functionality of this barrier has been poor, to the point that many believed that the fetal BBB 72 
is immature if not altogether absent. Across time this belief has been perpetuated, and it was 73 
believed protection of the growing fetus was provided solely by the placenta [4]. However, 74 
experiments performed nearly a century ago as well as several recent studies shows not only 75 
the presence of the BBB in the developing fetus but that it is functionally capable, possessing 76 
many of the barrier properties observed in the fully developed BBB of the adult brain [5]. In 77 
this review we will explore the development of the BBB, its function in the growing fetus 78 
and, how such changes in the maternal environment may impact the developing brain. 79 
 80 
Development of the blood-brain barrier  81 
The BBB is primarily a diffusional barrier between the systemic vascular system and the 82 
brain. Like the placenta, the BBB is responsible for maintaining an optimal environment for 83 
development. It does this through the complex cellular structure that makes up the BBB as 84 
well via a number of transport mechanisms responsible for molecule transfer and protection 85 
of the brain from toxic substances. The BBB is made up of endothelial cells of the 86 
vasculature forming cell-to-cell tight and adherens junctions to limit transcellular/paracellular 87 
movement between the two compartments. These endothelial cells lack fenestrations, have 88 
low turnover and proliferation rates, and have high electrical resistance [6]. Under normal 89 
conditions these properties limit the free movement of ions, large proteins, and water 90 
allowing tight control of concentration gradients between the blood and brain. This results in 91 
the protection of the brain from vasogenic edema, other toxic effects, and regulation of 92 
neuronal excitability. However, a fully functional BBB requires the support of a range of cell 93 
types including neurons, pericytes, astrocytes, and microglia, all of which contribute to 94 
barrier integrity; together these are known as the neurovascular unit (NVU). 95 
 96 
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Historically it was proposed that the BBB was not mature during early stages of development 97 
and that the vulnerable developing brain was fully protected by the barrier properties of the 98 
placenta. Early studies using vascularly injected dyes such as trypan blue in animal embryos 99 
and fetuses showed permeation into all tissues including the brain, perpetuating the idea that 100 
in the immature animal the BBB was undeveloped, leaky, or lacking altogether (for a 101 
comprehensive review see Saunders et al. 2014 [5]). However, several studies such as those 102 
by Weed (embryonic pig), Cohen and Davies (embryonic guinea pig) and Grazer (rat E10-103 
birth) did not show any evidence of staining in the brain [7-9]. In human, post-mortem tissue 104 
from fetuses and neonates showed that from as early as 12 weeks gestation trypan blue did 105 
not cross the BBB [10]. Overloading the binding capacity of plasma albumin, to which many 106 
dyes such as trypan blue bind, results in excess dye that can easily penetrate into the brain; in 107 
many of the early studies such toxic levels of dye were used that many animals died [5, 11].  108 
 109 
Structural development of the blood-brain barrier  110 
The precise structure of the BBB is key to its functional ability to protect and maintain the 111 
brain microenvironment. Recent studies have demonstrated that humans, rats, and sheep have 112 
a number of functional barrier mechanisms in place from early gestational time-points [12, 113 
13]. These include tight junction proteins and several transporters at the cerebral vasculature. 114 
 115 
The development of the BBB is a multistep process. Initial vascularisation is followed by 116 
tight junction protein and nutrient transporter expression. The BBB then matures further with 117 
contact of pericytes and astrocytes of the NVU [14]. Development continues with the 118 
increased expression of efflux transporters, decreased levels of transcytosis, and sealing of 119 
the inter-endothelial cleft. Across BBB development there are changes to the NVU, electrical 120 
resistance of the endothelial cells themselves, tight junction proteins, and influx and efflux 121 
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transport which may alter the permeability of the BBB to different substances such as water, 122 
proteins, or ions. Alterations to barrier structure and function address specific needs of the 123 
brain at various developmental stages. 124 
 125 
Vascularisation of the human telencephalon begins at approximately week 8 of gestation, by 126 
the 12th week tight junction proteins occludin and claudin-5 are expressed in the primary 127 
vessels [15]. The appearance of tight junction proteins at this time appears sufficient to 128 
prevent endogenous albumin from entering the brain, providing evidence of early 129 
functionality of the barrier  [15]. By the 18th week of gestation, these tight junction proteins 130 
demonstrate similar staining patterns to the tight junctions of the adult BBB [15]. Freeze 131 
fracture and thin section electron microscopy in neonatal human tissue demonstrates that tight 132 
junctions are organised in complex, linear, near-continuous tracts between endothelial cells of 133 
the microvasculature [16]. Similar detailed findings have been reported in rat BBB tight 134 
junction development, where tight junctions are abundantly present in late gestation and 135 
undergo increases in complexity in terms of integrity and length throughout gestation and 136 
after birth [17, 18].  137 
 138 
There are several studies demonstrating in vitro that astrocytes are essential for tight junction 139 
formation [19-21]. However, it has been demonstrated in rodents that tight junctions are 140 
present and functional at birth [18], whereas the primary period of astrocytic differentiation 141 
and vessel encirclement does not occur until the third postnatal week [22]. It is unclear how 142 
astrocytes contribute to the development of the barrier phenotype, however there is evidence 143 
to support a role in the progressive tightening of tight junctions after birth [23]. Another cell 144 
type critical for development and maintenance of the BBB is the pericyte [24]. While 145 
pericytes are expressed throughout the systemic vasculature, the highest density of pericytes 146 
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is found in the brain [24]. Pericytes have also been shown to be essential for the formation of 147 
tight junctions [24, 25]. Generation of pericytes and their effects on tight junction formation 148 
occur as early as P13 in the rodent preceding those of the astrocyte [24]. The process of 149 
pericyte encirclement of cerebral vessels is associated with a decrease in BBB solute 150 
permeability – demonstrating their functional importance in CNS protection [26]. 151 
 152 
How the development of the BBB across time affects barrier functionality is not well 153 
understood. It is clear that each of these changes is necessary for the tight control at the BBB 154 
demonstrable in adults. However, differences in permeability to drugs of differing size or 155 
pharmacological properties across development are unknown and likely to be species-156 
dependant. This presents challenges when targeting treatments towards the mother or fetus in 157 
the prediction of efficacy and toxic effects. These factors need to be kept in mind when 158 
studying the effects of the maternal environment on placental function and impacts on the 159 
CNS.  160 
 161 
Transport across the blood-brain barrier 162 
There are numerous transport mechanisms present at the BBB to provide the brain with 163 
essential nutrients and to provide protection from toxic substances. Transport at the BBB 164 
occurs via free-diffusion of small lipophilic substances or via catalysed transport processes 165 
such as carrier mediated transport, receptor-mediated transport, and active efflux transport. 166 
Efflux transport is essential for the protection of the brain from endogenous substances such 167 
as the excitatory neurotransmitter glutamate (although crucial for neuronal signalling, 168 
excessive levels are neurotoxic) and is key in regulating drug entry to the fetal brain [27, 28]. 169 
Present at high concentrations in the fetal circulation, glutamate levels in the brain are 170 
regulated at the BBB by the excitatory amino acid transporters (EAATs 1-4) [27]. 171 
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 172 
There are a number of transporter systems expressed throughout the body several of which 173 
are common to both the placenta and the BBB. Active efflux transporters come from two 174 
major classes of transporters which extrude metabolic waste, xenobiotics and a large number 175 
of drugs from the brain back into the blood. The first superfamily that has BBB efflux 176 
transporter members is the solute carrier proteins (SLC) superfamily. Transporters from three 177 
SLC subfamilies comprise the majority of known SLC efflux transporters. At the BBB these 178 
include SLC22 and SLCO (SLC21). The second, and most comprehensively studied of the 179 
efflux transporters at the BBB is the ATP-binding cassette (ABC) efflux transporter family. 180 
Permeability glycoprotein (P-gp) is an important member of this super family along with 181 
breast cancer resistance protein (BCRP) and the multidrug resistance associated proteins 182 
(MRPs) [29].  183 
 184 
Expression and Function of SLC efflux transporters 185 
SLC efflux transporters play an important role in elimination of organic compounds, 186 
especially organic anions, from the brain. Efflux members of this family are bi-directional 187 
transporters and commonly localise to the basolateral membrane of cerebral endothelial cells 188 
to remove toxic compounds from the brain extracellular space [30]. Unlike the ABC 189 
transporters much less is known about developmental expression changes to SLC efflux 190 
transporters at the BBB. Evidence from rodent models suggest that expression of Oat3 191 
(Slc22a8), which is present on endothelial cells of the BBB and at the choroid plexus, 192 
remains mostly unchanged across development [31-34]. Of the SLCO family Oatp1a4 193 
(Slco1a4) and Oatp1a5 (Slco1a5) are present on the rodent BBB with expression of 194 
Oatp1a4/Slco1a4 demonstrated to increase from P2 to P84 postnatal days, equivalent to that 195 
of human brain development from the preterm to the adult [34]. Oatp1a4 is located at both 196 
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apical and basolateral membranes in the rat brain, whereas Oatp1a5 membrane localisation is 197 
yet to be elucidated [35, 36]. In humans, OATP1A2 is the only isoform that shows relatively 198 
high homology with rodent Oatp1a4 and Oatp1a5. OATP1A2 is predominantly expressed in 199 
the brain at cerebral vasculature endothelial cells, however the membrane localisation is not 200 
yet clear [37] (Figure 1). 201 
 202 
Expression and function of ABC efflux transporters 203 
An important member of the ABC efflux transporter family, the P-gp transporter has a 204 
significant role in regulating drug transfer across both the placenta and BBB and a crucial 205 
role in neuroprotection [38, 39]. In the CNS, P-gp is primarily expressed on the luminal 206 
surface of endothelial cells of the cerebral vasculature as early as 8 weeks gestation [29, 40, 207 
41]. In contrast with placental P-gp expression which is maximal at the beginning of 208 
pregnancy and declines with increasing gestation, BBB protein and mRNA levels of P-gp are 209 
low and dramatically increase with advancing gestation in rodents and humans [42-45]. This 210 
suggests a compensatory mechanism that ensures continual protection of the brain from 211 
xenobiotics that are no longer sufficiently repelled by the placenta [46]. The mechanism of 212 
this action is unclear, however it is known that P-gp expression at the BBB appears to be 213 
regulated by glucocorticoids and, that BBB P-gp levels rise with a simultaneous increase in 214 
maternal and fetal cortisol levels [47, 48]. 215 
 216 
P-gp is involved in the transport of several prescription medications commonly administered 217 
to women during pregnancy to treat various conditions including asthma, hypertension, 218 
diabetes and epilepsy [49, 50]. Considering the highly lipophilic nature of such drugs the role 219 
of P-gp in excluding them from the fetal circulation is critical to protection of the developing 220 
fetus .However, P-gp may be altered by exposure to some drugs, and maternal factors such as 221 
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undernutrition have also been reported to impair P-gp expression both in the placenta and the 222 
brain potentially compromising placental function and may contribute to fetal exposure to 223 
potentially teratogenic drugs [39, 51]. 224 
 225 
Other efflux transporter membranes of the ABC superfamily are MRPs, specifically 1, 2, 4, 226 
and 5 which have definitive localisation on cerebral vessels [44, 52-54]. MRP homologs have 227 
a substantial degree of substrate overlap, and transport drugs conjugated to glutathione, 228 
sulphate, or glucoronate. Selected members may also transport endogenous substances such 229 
as leukotriene, bilirubin glucuronides and prostaglandins [53]. Expression of the MRPs at the 230 
BBB varies with MRP1, 2, and 5 located on the apical membrane of cerebral endothelial cells 231 
whereas MRP4 is equally distributed on apical and basolateral membranes (Figure 1) [54, 232 
55]. In rat forebrain it has been demonstrated that Mrp1 and 4 mRNA increase from 233 
embryonic day 13 through to postnatal time-points (P1 and P7 respectively) [44]. To date, 234 
changes to the developmental expression of MRP2 and 5 is unknown. 235 
BCRP removes a wide range of substances including chemotherapeutic agents, antiviral 236 
drugs, and carcinogens from the brain into the blood [56]. It is expressed on the apical 237 
membrane of the cerebral endothelial cells from early developmental ages and in rodents has 238 
been shown to be expressed from embryonic day 12.5 – approximately week 22 of human 239 
gestation [42, 44, 57, 58]. BCRP expression remains largely unchanged across development, 240 
with a moderate increase in mRNA found between postnatal ages and adult in the mouse and 241 
rat [33, 34]. 242 
 243 
Exploiting the fetal blood-brain barrier  244 
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P-gp transporters repel many classes of prescription and illicit drugs from the brain. These 245 
drugs include calcium channel blockers, statins, opioids, chemotherapies, HIV protease 246 
inhibitors, and anti-epileptic drugs [59]. Many women require prescription drugs that are 247 
substrates of the P-gp transporter throughout pregnancy, either for acute or chronic conditions 248 
such as asthma, epilepsy, or cancer. In the early 2000’s, the percentage of pregnant women 249 
who used prescription drugs ranged from 27 to 93% [60-62].  250 
 251 
Improved understanding of drug transport systems at the BBB during development could 252 
allow exploitation of endogenous systems for the protection of the fetal brain. Exogenous 253 
glucocorticoids such as those given to pregnant women at risk of premature birth can result in 254 
premature maturation of P-gp expression and function at the BBB as demonstrated in in vitro 255 
experiments [46, 51]. This effect may be particularly useful in babies at risk of brain damage 256 
due to prescription or illicit drug use in the mother. It must be noted, however, that P-gp also 257 
regulates entry of substrates such as cortisol and aldosterone that are required for normal 258 
brain development [46]. 259 
 260 
Conversely, a reduction in P-gp function is of interest clinically to enhance the delivery of 261 
drugs to specifically treat CNS pathologies in the fetus. Selective serotonin reuptake 262 
inhibitors (SSRIs) have been identified as a class of drug that inhibit P-gp transporters at the 263 
BBB [63]. However, sertraline (a member of the SSRI family) has the opposite effect on 264 
function of P-gp at the placenta. Mice treated with sertraline had increased efflux function of 265 
the P-gp transporter at the placenta, and decreased P-gp transporter function at both the fetal 266 
and maternal BBB [63]. These tissue specific effects emphasise the need to understand 267 
transport functions at both the placenta and BBB in the development of novel therapies. 268 
 269 
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Illicit drug use during pregnancy in the United States has been estimated to be approximately 270 
16% in teenagers, and 7% in women 18-25 years of age [64]. There is a population of women 271 
who seek assistance from physicians for opioid maintenance with methadone or 272 
buprenorphine [65]. Exploiting the developing BBB in the fetus has been proposed as a novel 273 
therapy to prevent neonatal abstinence syndrome without significant effects on maternal 274 
maintenance. A selective opioid antagonist has been identified that crosses the placenta and 275 
fetal BBB without substantial effects on the maternal BBB opioid receptors [66]. Oberdick 276 
and colleagues suggest that is it the immaturity of the BBB in the neonatal mouse (equivalent 277 
to a fetal human) that allows the opioid antagonist 6β-naltrexol to cross into the brain and 278 
exert its effect. While such results are encouraging, species differences in BBB development 279 
is an important consideration. Significant alterations in the timing of BBB development have 280 
been noted in humans when compared with other mammals. It is also worth noting that there 281 
are several other routes into the brain such as the blood CSF barrier which may affect studies 282 
that manipulate developmental differences [67]. 283 
 284 
Other avenues to exploit the BBB include development of therapies to increase biochemical 285 
barrier function at the BBB and placenta and therefore decrease fetal exposure and toxicity. 286 
Nanoparticles are a promising area of research where a drug can be encapsulated for targeted 287 
delivery to specific tissues. In the case of maternal CNS disorders, direct targeting would 288 
increase the proportion of drug reaching the maternal brain, reducing the dose available to 289 
cross the placenta and reach the fetus [68]. Liposomal encapsulation may significantly reduce 290 
placental transfer of drugs such as the anti-epileptic drug valproic acid [69]. It was postulated 291 
that this technique may be useful in the treatment of maternal CNS disorders such as epilepsy 292 
without exposing the fetus to significant amounts of drug. However, it is unclear how this 293 
modification would affect transport through the maternal BBB and therefore disease control. 294 
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This technique reduces the risk in manipulation of placental transporters and potential off 295 
target effects such as unintended alteration of BBB transport function. However, 296 
advancement in encapsulation technology needs to occur before it can be applied clinically 297 
[68].  298 
 299 
Conclusion 300 
Despite the presence of placental efflux transporters, the placenta is an imperfect drug barrier. 301 
Given sufficient time and dosage most drugs can breach the placenta and enter the fetal 302 
circulation, posing a teratogenic risk to the fetal brain. Although the placenta and BBB have 303 
several efflux transporters in common, the BBB is a far more structurally complex and 304 
restrictive system. To cross the BBB and enter the CNS, drugs need to be small and lipophilic 305 
or have dedicated transport systems. Drugs with these properties would easily cross the 306 
placental barrier even with functional efflux transporters, as quick diffusion surpasses the 307 
ability of efflux transporters to pump substances from the fetal circulation. Understanding 308 
how the BBB functions during development of the fetus is essential to ensuring optimal brain 309 
growth and protection from drugs and toxins once they cross the placenta. Given the 310 
differences in BBB development across species, refinement of animal models is critical 311 
before application to the human.  312 
 313 
Minimising drug exposure in the fetus is vital to reducing teratogenic effects, and long-term 314 
neurological disease. Recently it has been shown that valproate, and other anti-epileptic drugs 315 
such as phenytoin and topiramate during pregnancy can result in long-term reductions in IQ 316 
and behavioural consequences [70]. Stolp and Dziegielewska (2009) have previously 317 
reviewed the role of disruption to the BBB  during development in the onset of serious 318 
neurological diseases such as Alzheimer’s disease and multiple sclerosis [71]. It is unclear at 319 
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this stage the long-term functional consequences of changes to transporters at the BBB during 320 
development. 321 
 322 
It is important to note that there are a number of relevant additional factors to consider that 323 
have not been addressed in this review. Drug metabolising enzymes at the BBB and placenta 324 
may significantly affect drug transfer through these barriers, and biotransformation by these 325 
enzymes may affect movement of substances by barrier efflux transporters [72, 73]. Drug 326 
metabolising enzymes with actions at the BBB include phase I and phase II enzymes such as 327 
cytochrome P450 and glutathione S-transferases [74]. In addition, there are other routes into 328 
the brain other than the BBB, these include the blood-CSF barrier between the systemic 329 
blood supply and the choroid plexus, the meningeal barrier, and the fetal-specific CSF-brain 330 
barrier [11]. These factors are an additional source of complexity when considering how best 331 
to protect the developing brain. 332 
 333 
A significant clinical challenge is the protection of the vulnerable fetal brain from drugs in 334 
the maternal environment. The changes in placental or BBB function due to drug exposure 335 
from the maternal environment have significant clinical relevance as the functional outcomes 336 
vary and are often unknown. Greater consideration needs to be paid to the relationship 337 
between placental adaptation to the maternal environment and changes to other barrier 338 
systems in the fetus such as the BBB to fully understand the functional consequences of these 339 
changes. In addition, transporter systems of the placenta and BBB and the effect of substrates 340 
and inhibitors needs to be further elucidated. A more comprehensive understanding of these 341 
systems may allow exploitation of transport in order to better treat and protect the fetal brain. 342 
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